OMEROS CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
OMEROS CORP (OMER) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $14.85 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2022-03-01
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $15.26, a 1.46% increase year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2020-03-31 was $15.04, a 2.52% increase year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2019-03-31 was $14.67, a 7.15% decline year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $15.80, a 51.34% increase year-over-year.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $14.85, a 22.32% increase from fiscal 2020.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2020 was $12.14, a 25.43% decline from fiscal 2019.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2019 was $16.28, a 21.31% increase from fiscal 2018.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2018 was $13.42, a 20.58% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2021-12-31 | $14.85 10-K · filed 2022-03-01 | |||
| 2021-03-31 | $15.26 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $12.14 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $11.29 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $14.32 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $15.04 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $16.28 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $16.07 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $14.31 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $14.67 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $13.42 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $13.39 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $13.58 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $15.80 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $11.13 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $10.97 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $10.80 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $10.44 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $12.92 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $13.99 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $14.02 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $14.51 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $12.36 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $13.28 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $13.52 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $12.19 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $10.30 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $9.82 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | $9.90 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $9.80 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $7.52 10-K · filed 2014-03-13 | |||
| 2013-09-30 | $7.42 10-Q · filed 2013-11-07 | |||
| 2013-06-30 | $7.45 10-Q · filed 2013-08-09 | |||
| 2013-03-31 | $7.63 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $6.90 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $6.14 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | $6.25 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |